IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Conditions

• Acute Myeloid Leukemia
• Chronic Myelomonocytic Leukemia

Interventions

• DRUG: Enasidenib

Sponsor

Massachusetts General Hospital

Collaborators

• [object Object]